Abstract:Tumor-associated macrophages (TAMs) are predominantly present in the tumor microenvironment (TME) and play a crucial role in shaping the efficacy of tumor immunotherapy. These TAMs primarily exhibit a tumor-promoting M2-like phenotype, which is associated with the suppression of immune responses and facilitation of tumor progression. Interestingly, recent research has highlighted the potential of repolarizing TAMs from an M2 to a pro-inflammatory M1 status-a shift that has shown promise in impeding tumor growth and enhancing immune responsiveness. This concept is particularly intriguing as it offers a new dimension to cancer therapy by targeting the tumor microenvironment, which is a significant departure from traditional approaches that focus solely on tumor cells. However, the clinical application of TAM-modulating agents is often challenged by issues such as insufficient tumor accumulation and off-target effects, limiting their effectiveness and safety. In this regard, nanomaterials have emerged as a novel solution. They serve a dual role: as delivery vehicles that can enhance the accumulation of therapeutic agents in the tumor site and as TAM-modulators. This dual functionality of nanomaterials is a significant advancement as it addresses the key limitations of current TAM-modulating strategies and opens up new avenues for more efficient and targeted therapies. This review provides a comprehensive overview of the latest mechanisms and strategies involving nanomaterials in modulating macrophage polarization within the TME. It delves into the intricate interactions between nanomaterials and macrophages, elucidating how these interactions can be exploited to drive macrophage polarization towards a phenotype that is more conducive to anti-tumor immunity. Additionally, the review explores the burgeoning field of TAM-associated nanomedicines in combination with tumor immunotherapy. This combination approach is particularly promising as it leverages the strengths of both nanomedicine and immunotherapy, potentially leading to synergistic effects in combating cancer.

Modulating Repolarization of Tumor-Associated Macrophages with Targeted Therapeutic Nanoparticles as a Potential Strategy for Cancer Therapy

Nanomaterials in modulating tumor-associated macrophages and enhancing immunotherapy

Reprogramming Tumor Associated Macrophages Toward M1 Phenotypes with Nanomedicine for Anticancer Immunotherapy

Macrophage-modulating nanomedicine for cancer immunotherapy

Reprogramming Tumor-Associated Macrophage Using Nanocarriers: New Perspectives to Halt Cancer Progression

Recent Progress on Nanomedicine-Mediated Repolarization of Tumor-Associated Macrophages for Cancer Immunotherapy

Nanoparticles targeting tumor-associated macrophages: A novel anti-tumor therapy

Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy

Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Mir-182 Targeting Reprograms Tumor-Associated Macrophages and Limits Breast Cancer Progression

Targeting Tumor-Associated Macrophages As an Antitumor Strategy.

The Polarization of Tumor-Associated Macrophages as an Effective Therapeutic Strategy: A Comprehensive Analysis

Targeting tumor-associated macrophages for cancer treatment

Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer

Nanomaterials-Involved Tumor-Associated Macrophages' Reprogramming for Antitumor Therapy

Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy

Targeting tumor-associated macrophages to synergize tumor immunotherapy

In Situ Reprogramming of Tumor-Associated Macrophages Enhances Cancer Immunotherapy

Roles of Tumor-Associated Macrophages in Tumor Environment and Strategies for Targeting Therapy

Research advances on signaling pathways regulating the polarization of tumor-associated macrophages in lung cancer microenvironment